PMC:7299399 / 17295-17584
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T77 | 57-64 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T78 | 69-72 | Body_part | denotes | RNA | http://purl.org/sig/ont/fma/fma67095 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T183 | 49-50 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T106 | 51-55 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T107 | 57-64 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T78 | 0-162 | Sentence | denotes | There are many issues related to the delivery of a drug, protein, or RNA into the patient as the cargo is often degraded, not bioavailable, or is swiftly cleared. |
| T79 | 163-289 | Sentence | denotes | Nanotechnology provides multiple solutions to these challenges though, as nanocarriers can overcome some of these limitations. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 261 | 82-89 | Species | denotes | patient | Tax:9606 |